Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 3
Submit an article Journal homepage
232
Views
61
CrossRef citations to date
0
Altmetric
Research Article

Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias

Tadeusz Robak Department of Hematology, Medical University of Lodz, 93-513 Lodz, Pabianicka 62, Poland
Pages 391-409 | Published online: 01 Jul 2009

  • Tollman, M.S. and Hakimian, D. (1995) "Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders", Blood 86, 2463-2474.
  • Robak, T. (2002) 'The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials", Leukemia and Lymphoma 43, 537-548.
  • Adkins, J.C., Peters, D.H. and Markhan, A. (1997) "Fludarabine. An update of its pharmacology and use in the treatment of hematological malignancies", Drugs 53, 1005-1037.
  • Robak, T. (2001) "Cladribine in the treatment of chronic lymphocytic leukemia", Leukemia and Lymphoma 40, 551-564.
  • Gandhi, V. (1993) "Fludarabine for treatment of adult acute myelogenous leukemia", Leukemia and Lymphoma 11(Suppl. 2), 7-13.
  • Santana, V.M., Mirro, Jr., J., Harwood, EC., Cherrie, I., Schell, M., Kalwinsky, D. and Blakley, R.L. (1991) "A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia", Journal of Clinical Oncology 9, 416-422.
  • Santana, V.M., Mirro, Jr., J., Kearns, C., Schell, M.J., Cram, W. and Blakley, R.L. (1992) "2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia", Journal of Clinical Oncology 10, 364-370.
  • Santana, V.M., Hurwitz, C.A., Blakley, R.L., Cram, W.R., Luo, X., Roberts, W.M., Ribeiro, R., Mahmoud, H. and Krance, R.A. (1994) "Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia", Blood 84, 1237-1242.
  • Van Den Neste, E., Martial, P., Mineur, P., Delannoy, A., Doyen, C., Zenebergh, A., Michaux, J.L. and Ferrant, A. (1998) "2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia", Annals of Hematology 76, 19-23.
  • Kornblau, S.M., Gandhi, V, Andreeff, H.M., Reran, M., Kantarjian, H.M., Koller, C.A., O'Brien, S., Plunkett, W. and Estey, E. (1996) "Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults", Leukemia 10, 1563-1569.
  • Gordon, M.S., Young, M.L., Tollman, M.D., Cripe, L.D., Bennett, J.M., Paietta, E., Longo, W., Gerad, H., Mazza, J. and Rowe, J.M. (2000) "Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995", Leukemia Research 24,871-875.
  • Krance, R.A., Hurwitz, C.A., Head, D.R., Raimondi, S.C., Behm, F.G., Crewsk, R., Srivastava, D.K., Mahmoud, H., Roberts, W.M., Tong, X., Blakley, R.L. and Ribeiro, R.C. (2001) "Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic disease", Journal of Clinical Oncology 19, 2804-2811.
  • Saven, A., Piro, L.D., Lemon, R.H., Figueroa, M.L., Kosty, M., Ellison, D.J. and Beutler, E. (1994) "Complete hematologic remissions in chronic-phase, Phildalephia-chromosome-positive chronic myelogenous leukemia after 2-chlorodeoxyadenosine", Cancer 73, 2953-2963.
  • Gollard, R., Miller, W.E., Piro, L.D. and Saven, A. (1997) "2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia", Leukemia and Lymphoma 28, 183-185.
  • Cortes, J., Kantarjian, H., Talpaz, M., O'Brien, S., Heran, M., Koller, C. and Rearing, M. (1997) 'Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine", Leukemia 11, 788-791.
  • Robak, T. and Gora-Tybor, J. (2001) "Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia", Neoplasma 48, 203-207.
  • Carrera, C.I., Saven, A. and Piro, L.D. (1994) "Purine metabolism of lymphocytes. Targets for chemiotherapy drug development", Hematology-Oncology Clinics of North America 8, 357-381.
  • Plunkett, W., Huang, P. and Gandhi, V. (1990) "Metabolism and action of fludarabine phosphate", Seminars in Oncology 17(Suppl. 8), 3-17.
  • Hentosh, P., Koob, R. and Blakley, R.L. (1990) "Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta", Journal of Biological Chemistry 265, 4033-4040.
  • Hentosh, P., McCastlain, I.C. and Blakley, R.L. (1991) "Effects of 2-chloro-2-deoxyadenosine 5-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerases", Biochemistry 30, 547-554.
  • Crawford, C.R., Ng, C.Y., Noel, L.D. and Belt, J.A. (1990) "Nucleoside transport in L1210 marine leukemia cells. Evidence for three transporters", Journal of Biological Chemistry 65, 9732-9736.
  • Gandhi, V. and Plunkett, W. (2001) "Combination strategies for purine nucleoside analogs", In: Cheson, B.D., ed, Chronic Lymphoid Leukemias (Marcel Dekker, New York), pp. 195-208.
  • Seymour, I.F., Huang, P., Plunkett, W. and Gandhi, V. (1996) "Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule", Clinical Cancer Research 2, 653-658.
  • Gandhi, V. and Plunkett, W. (2002) "Cellular and clinical pharmacology of fludarabine", Clinical Pharmacokinetic 41, 93-103.
  • Robertson, L.E., Chubb, S., Meyn, R.F., Story, M., Ford, R., Hittelman, W.N. and Plunkett, W. (1993) "Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2deoxyadenosine and 9-ß-D-arabinosyl-2-fluoroadenine", Blood 81, 143-150.
  • Zinzani, P.L., Tosi, P. and Visani, G. (1994) "Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemic cells", American Journal of Hematology 47, 301-306.
  • Beutler, E. (1992) "Cladribine (2-chlorodeoxyadenosine)", Lancet 340, 952-956.
  • Genini, D., Adachi, S., Chao, Q., Rose, D.W., Carrera, C.J., Cottani, H.B., Carson, D.A. and Leoni, L.M. (2002) "Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly effecting the mitochondria", Blood 96, 3537-3543.
  • Niitsu, N., Yamaguchi, Y, Umeda, M. and Honma, Y. (1998) "Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2-deoxycoformycin and 2-deoxyadenosine: association with dATP-dependent activation of caspase-3", Blood 92, 3368-3375.
  • Nitisu, N., Yamamoto-Yamaguchi, Y, Kasukabe, T., Okabe-Kado, I., Umeda, M. and Honma, Y (2000) "Antileukemic efficacy of 2-deoxycoformycin in monocytic leukemia cells", Blood 96, 1512-1516.
  • Foran, I.M., Oscier, D., Orchard, I., Johnson, S.A., Tighe, M., Cullen, M.H., de Takats, P.G., Krans, C., Klein, M. and Lister, T.A. (1999) "Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia", Journal of Clinical Oncology 17, 1574-1579.
  • Oscier, D., Orchard, I.A., Culligan, D., Cunningham, D., Johnson, S., Parker, A., Klein, M. and Gieschen, H. (2001) "The bisoavailability of oral fludarabine phosphate is unaffected by food", Hematology Journal 2, 316-321.
  • Gandhi, V, Kemena, A., Rearing, M.I. and Plunkett, W. (1993) "Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cell during fludarabine therapy", Leukemia and Lymphoma 10, 49-56.
  • Liliemark, I. and Juliusson, G. (1991) "On the pharmacokinetics of 2-chloro-2-deoxyadenosine in humans", Cancer Research 51, 5570-5572.
  • Lilemark, I., Albertioni, F., Hassan, M and Juliusson, G. (1992) "On the bioavailability of oral and subcutaneous 2-ChIoro-2deoxyadenosine in humans: alternative routes of administration", Journal of Clinical Oncology 10, 1514-1518.
  • Albertioni, F., Juliusson, G. and Liliemark, I. (1993) "On the bioavailability of 2-chloro-2-deoxyadenosine (CdA). The influence of food and omeprazole", European Journal of Clinical Pharmacology 44, 579-582.
  • Petzer, A.L., Bilgeri, R., Zilian, U., Haun, M., Geisen, F.H., Pragnell, I., Braunsteiner, H. and Konwalinka, G. (1991) "Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth", Blood 78, 2583-2587.
  • Robak, T., Korycka, A. and Gora-Tybor, I. (1994) "The interaction of 2-chlorodeoxyadenosine (2-CdA) and interferon-alpha (IFNalpha) on normal and myeloid leukemia hematopoiesis in vitro". Leukemia Research 18, 275-281.
  • Nagourney, R.A., Evans, S.S., Messenger, I.C., Su, Y.Z. and Weisenthal, L.M. (1993) "2-chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms", British Journal of Cancer 67, 10-14.
  • Carson, D.A., Wasson, D.B., Taetle, R. and Yu, A. (1983) "Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes", Blood 62, 737-743.
  • Schirmer, M., Geisen, F., Tiefenthaler, M. and Konwalinka, G. (1999) "Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia", Leukemia Research 23, 1121-1126.
  • Niitsu, N., Umeda, M. and Honma, Y. (2000) "Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs", Leukemia Research 24, 1-9.
  • Niitsu, N., Yamamoto-Yamaguchi, Y, Kasukabe, T., Okabe-Kado, I., Umeda, M. and Honma, Y. (2000) "Antileukemic efficacy of 2-deoxycoformycin in monocytic leukemia cells", Blood 96, 1512-1516.
  • Honma, Y. and Niitsu, N. (2000) "Vidarabine and 2-deocycoformycin as antileukemic agents against monocytic leukemia", Leukemia and Lymphoma 39, 57-66.
  • Honma, T. (2001) "A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and deaminase inhibitors", Leukemia and Lymphoma 42, 353-362.
  • Gandhi, V, Estey, E., Rearing, M.J. and Plunkett, W. (1993) "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy", Journal of Clinical Oncology II, 116-124.
  • Gandhi, V, Estey, E., Du, M., Rearing, M.J. and Plunkett, W. (1997) "Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabino-furanosylcytosine triphosphate in human leukemia blasts during therapy", Clinical Cancer Research 3, 1539-1545.
  • Kufe, D., Spriggs, D., Egan, E.M. and Munroe, D. (1984) "Relatioships among Ara-CTP pools, formation of (Ara-C) DNA, and cytotoxicity of human leukemic cells", Blood 64, 54-58.
  • Gandhi, V. and Plunkett, V. (1988) "Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells", Cancer Research 48, 329-334.
  • Gandhi, V, Estey, E., Reating, M.J., Chuacrallah, A. and Plunkett, W. (1996) "Chlorodeoxyadenosine and arabinosyl cytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions", Blood 87, 256-264.
  • Rristensen, J., Nygren, P., Liliemark, J., Fridborg, H., Killander, A., Simonsson, B., Oberg, G. and Larsson, R. (1992) "Inteactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia", Leukemia 8, 1712-1717.
  • Gandhi, V, Plunkett, W., Waller, S., Du, M., Ayres, M., Rodriguez, Jr., CO., Ramakrishna, P., Rosner, G.L., Hodge, J.P., O'Brien, S. and Reating, M.J. (2001) "Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells", Journal of Clinical Oncology 19, 2142-2152.
  • Warrell, Jr., R.P. and Herman, E. (1986) "Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity", Journal of Clinical Oncology 4, 74079.
  • Spriggs, D.R., Stopa, E., Mayer, R.I., Schoene, W. and Kufe, D.W. (1986) "Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study", Cancer Research 46, 5953-5958.
  • Chun, H.G., Leyland-Jones, B.R., Caryk, S.M. and Hoth, D.F. (1986) "Central nervous system toxicity of fludarabine phosphate", Cancer Treatment Report 70, 1225-1228.
  • Michelutti, A., Michieli, M. and Damiani, W. (1997) "Effect of fludarabine and arabinosylcytosine on multidrug-resistant cells", Haematologica 82, 143-147.
  • Estey, E., Plunkett, W, Gandhi, V, Rios, M.B., Kanatrjian, H. and Keating, M. (1993) "Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia", Leukemia and Lymphoma 9, 343-350.
  • Kornblau, S.M., Cortes-Franco, J. and Estey, E. (1993) "Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia", Leukemia 7, 378-383.
  • Sato, J., Wiesma, S., Krailo, M., Bostrom, B., Shurin, S., Cheerva, A., Hammond, D. and Avramis, S. (1992) "Phase I clinical and phaimacodynamic study of continuous infusion (CI) cytosine arabinoside (Ara-C) in relapsed leukemia", Proceedings of the American Association for Cancer Research 33, 211.
  • Vidarsson, B., Abonour, R., Williams, E.G., Woodson, R.D., Turraan, N.J., Kim, K., Mosher, D.F., Wiersma, S.R. and Longo, W.L. (2001) "Fludarabine and cytarabine as sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia", Leukemia and Lymphoma 41, 321-331.
  • Avramis, V, Viersma, S., Chang, A., Sato, I. and Holcenberg, J. (1989) "Selective pharmacological synergism between F-ara A and ara-C in human leukemic cells in vitro and in vivo". Proceedings of the American Society of Clinical Oncology 8,215.
  • Estey, E., Thall, P., Andreeff, M., Heran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C, Kornblau, S. and Pierce, S. (1994) "Use of granulocyte colony-stimulating factor before, during and after fludarabine", Journal of Clinical Oncology 12, 671-678.
  • Van der, L., De Witte, T., Wessels, J., Raymakers, R., Muus, P. and Preijers, F. (1994) "In vitro response of blasts to IL-3, GM-CSF and G-CSF is different for individuals AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity", Annals of Hematology 68, 225-232.
  • Te Boekhorst, P.A., Lowenberg, B. and Sonneveld, P. (1994) "Hematopoietic growth factor stimulation and cytarabine toxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells", Leukemia 8, 1480-1486.
  • Visani, G., Tosi, P., Zinzani, PL., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberi, B., Carrara, P., Gobbi, M. and Tura, S. (1994) "FLAG (Fludarabine + High-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemis", Leukemia 8, 1842-1846.
  • Nokes, T.J.C., Johnson, S., Harvey, D. and Goldstone, A.H. (1997) "FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodysplastic syndromes", Leukemia and Lymphoma 27, 93-101.
  • Huhmann, I.M., Watzke, H.H., Geissler, K., Gisslinger, H., Jager, U., Knobl, P., Pabinger, I., Kominger, L., Mannhalter, C., Mitterbauer, G., Schwarzinger, I., Kalhs, P., Haas, D.A. and Lechner, K. (1996) "FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myleoid leukemia", Annals of Hematology 73, 265-271.
  • Montillo, M., Mirto, S., Petti, M.C., Latagliata, R., Magrin, S., Pinto, A., Zagonel, V, MeIe, G., Tedeschi, A. and Ferrara, F. (1998) "Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia", American Journal of Hematology 58, 105-109.
  • Jackson, G., Taylor, P., Smith, G.M., Marcus, R., Smith, A., Chu, P., Littlewood, T.J., Hutchunson, M., Mehta, A.B., Johnson, S.A., Carey, P., Turner, G.E., Deane, H., Schey, S., Brookby, I., Tollerfield, S.M., Duncombe, A., Macke, M.I., Ganly, P.S. and Wilson, M.P. (2001) "A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony--stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation", British Journal of Hematology 112, 127-137.
  • McCarthy, A.J., Pitcher, L.A., Hann, I.M. and Oakhill, A. (1999) "FLAG (Fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children", Medical and Pediatric Oncology 32, 411-415.
  • Ferrara, P., Palmieri, S., Pocali, B., Pollio, F., Vida, A., Aununziatas, S., Sebastio, L., Schiavone, E.M., MeIe, G., Gianfaldoni, G. and Leoni, F. (2002) "De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients trated with fludarabine, cytarabine and G-CSF (FLAG)", European Journal of Hematology 68, 203-209.
  • Ferrara, F., Melillo, L., Montillo, M., Leoni, P., Pinto, A., MeIe, G. and Mirto, S. (1999) "Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation", Annals of Hematology 78, 380-384.
  • Carella, A.M., Cacavilla, N., Greco, M.M., Melillo, L., Sajeva, M.R., Ladogana, S., D'Arena, G., Perla, G. and Carotenuto, M. (2001) 'Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (FLAC, regimen): a single centre study", Leukemia and Lymphoma 40, 295-303.
  • Visani, G., Tosi, P., Zinzani, P.L., Manfroi, S., Ottaviani, E., Cenacchi, A., Carrara, P., Clavio, M, Gobbi, H. and Tura, S. (1996) "FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects", European Journal of Hematology 56, 308-312.
  • De Ia Rubia, J., Regadera, A.J., Martin, G., Cervera, I., Sanz, G.F., Martinez, J.A., Jarque, I., Garcia, I., Andrea, R., Moscardo, F., limenez, C., Molla, S., Benlloch, L. and Sanz, M.A. (2002) "FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies", Leukemia Research 26, 725-730.
  • Ross, D.D., Doyle, L.A., Yang, W., Tong, Y. and Comblait, B. (1995) "Susceptibility of idarubicin, daunorubicin and their C-13 alcohol metabolites to transport-mediated multidrug resistance", Biochemical Pharmacology 50, 1673-1683.
  • Muller, M.R., Lennartz, K., Boogen, C., Nowrousian, M.R., Rajewsky, M.A. and Seeber, S. (1992) "Cytotoxicity of adriamycin, idarubicin and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression", Annales of Hematology 65, 206-212.
  • Anderlini, P., Benjamin, R.S., Wong, F.C., Kantarjian, H.M., Andreef, M., Kornblau, S.M., O'Brien, S., Mackay, B., Ewer, M.G., Pierce, S.A. and Estey, H.M. (1995) "Idarubicin cardiotoxicity, a retrospective study in acute myeloid leukemia and myelodysplasia", Journal of Clinical Oncology 13, 2827-2834.
  • Grant, S., Arlin, Z., Gewirtz, D. and Feldman, E. (1991) "Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blasts progenitors", Leukemia 5, 336-339.
  • Feldman, E.J., Seiter, K., Damon, L., Linker, C., Rugo, H., Ries, C., et al. (1997) "A randomized trial of high-vs. standard dose mitoxantrone, with cytarabine in elderly patients with acute myeloid leukemia", Leukemia 11, 485-489.
  • Fleischhack, G., Hasan, C, Graf, N., Mann, G. and Bode, U. (1998) "IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor prognosis AML of childhood prior to allogenic or autologues bone marrow transplantation: experiences of a phase II trial", British Journal of Haematology 102, 647-655.
  • Steinmetz, H.T., Schulz, A., Staib, P., Scheid, C., Glasmacher, A., Neufang, A., Franklin, J., Tesch, H., Diehl, V. and Dias Wickramenayake, P. (1999) "Phase D trial or idarubicin, fludarabine, cytosine arabinoside and filigrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML", Annals of Hematology 78, 418-425.
  • Parker, I.E., Pagliuca, A., Mijovic, A., Cullis, J.O., Czepulkowski, B., Rassam, S.M., Samaratunga, I.R., Grace, R., Cover, P.A. and Mufti, G.J. (1997) "Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) in the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia", British Journal of Hematology 99, 939-944.
  • Koller, C.A., Kantarjian, H.M., Feldman, E.J., O'Brien, S., Rios, M.B., Estey, E. and Rearing, M. (1999) "A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for pateints with acute leukemia and the blastic phase of chronic myelogenous leukemia", Cancer 86, 2246-2251.
  • Estey, E.H., Thall, P.F., Pierce, S., Cortes, J., Reran, M., Kantarjian, H., Rearing, M.J., Andreeff, M. and Freireich, E. (1999) "Randomized phase II study of fludarabine-cytosine arabinoside + idarubicin ± all irons retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myleoid leukemia and myelodysplastic syndrome", Blood 93, 2478-2484.
  • Russo, D., Pricolo, G., Michieli, M., Michelutti, A., Raspadori, D., Bertone, A., Marin, L., Pierri, I., Bucalossi, A., Zuffa, E., De Vivo, A., Mazza, P., Gobbi, M., Lauria, F., Zaccaria, A. and Baccarani, M. (2001) "Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myleoid leukemia", Leukemia and Lymphoma 40, 335-343.
  • Kern, W., Schleyer, E., Braess, J., Winner, E., Ohnesorge, J., Unterhalt, M., Wormann, B., Buchner, T. and Hiddeman, W. (2001) "Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias", Annals of Hematology 80, 334-339.
  • Clavio, M., Carrara, P., Miglino, M., Pierri, I., Canepa, L., Balleari, E., Gatti, A.M., Cerri, R., Celesti, L., Vallebella, E., Sessarego, V, Patrone, F., Ohio, R., Damasio, E. and Gobbi, M. (1996) "High efficacy of fludarabine-containing therapy (FLAGFLANG) in poor risk acute myeloid leuekmia", Haematologica 81, 513-520.
  • Mazza, P., Amurri, B., Palazzo, G., Prudenzanio, A., Pricolo, G. and Stani, L. (2000) "Fludarabine-containing regimen followed by autologous peripheral blood stem cell transplantation in unselected patients with acute myeloid leukemia: a single center experience", Haematologia 85, 222-224.
  • Hanel, M., Friedrichsen, K., Hanel, A., Herbst, R., Morgner, A., Neser, S., Nicklisch, M., Teich, M., Ehninger, G. and Fiedler, F. (2001) "Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia", Onkologie 24, 356-360.
  • Clavio, M., Gatto, S., Beltrami, G., Cerri, R., Carrara, P., Pierri, I., Canepa, L., Miglino, M., Balleari, E., Masoudi, B., Damasio, E., Ghio, R., Sessarego, M. and Gobbi, M. (2001) "First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia", Leukemia and Lymphoma 40, 305-313.
  • Salvucci, M., Zanchini, R., Molinari, A., Zuffa, E., Poletti, V, Poletti, G. and Zaccaria, Al. (2000) "Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (FLAN) treatment for acute leukemia", Haematologica 85, 769-770.
  • Levin, M., Aziz, M. and Opitz, L. (1997) "Steroid responsive interstitial pneumonitis after fludarabine therapy", Chest 111, 1472-1473.
  • Leoni, F, Ciolli, S., Nozzoli, C., Santini, V, Fand, R. and RossiFerrini, P. (2001) "Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report", Haematologica 86, 104.
  • Beutler, E., Piro, L., Saven, A., Kay, A.C., McMillan, R., Longmire, R., Carrera, C.I., Morin, P. and Carson, D.A. (1991) "2-chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside", Leukemia and Lymphoma S, 1-8.
  • Bryson, H.M. and Sorkin, E.M. (1993) "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies", Drugs 46, 872-894.
  • Vahdat, L. and Warrel, Jr., R.P. (1993) 'Treatment of acute myeloblastic leukemia in adults with 2-chlorodeoxyadenosine", Blood 82(Suppl. 1), 129a, (Abstract).
  • Vahdat, L., Wong, E., Wile, M., Rosenblum, M., Foley, K.M. and Warell, Jr., R.P. (1994) "Therapeutic and neutrotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia", Blood 84, 3429-3434.
  • Gandhi, V, Estey, E., Rearing, M.J., Chucrallah, A. and Plunkett, W. (1996) "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions", Blood 87, 256-264.
  • Robak, T., Wrzesien-Kus, A., Lech-Maranda, E., Kowal, M. and Dmoszynska, A. (2000) "Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia", Leukemia and Lymphoma 39, 121-129.
  • Juliusson, G. and Liliemark, J. (1994) "2-chlorodeoxyadenosine (CDA) with and without cytosine arabinoside (Ara-C) and idarubicin for acute myeloid and lymphoid leukemia-clinical and pharmacokientic studies", British Journal of Haematology 87, 48a, (Abstract).
  • Juliusson, G., Lofgren, C., Mollgard, L., Paul, C., Hoglund, M., Tidefelt, U. and Bjorkholm, M. (2001) "No additional toxicity from cladribine (CdA) when given with cytosine arabinoside and idarubicin (CCT) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase D study from the Leukemia Group of Middle Sweden (LGMS)", Blood 98,123a, (Abstract 518).
  • Holowiecki, I., Robak, T, Kyrcz-Krzemien, S., Grosicki, S., Wrzesien-Kus, A., Hellmann, A., Skotnicki, A., ledrzejczak, W., Konopka, L. and Zdziarska, B. (2002) "Daunorubicin, cytarabine and 2-CdA (DAC-7) for remission induction in "de novo" adult acute myleoid leukemia patients", Acta Haematologica Polonica 33, 839-847.
  • Hotowiecki, J., Grosicki, S., Robak, T., Kizemien, S., Hellmann, A., Skotnicki, A., Jedizejczak, W., Kuliczkowski, K., Kbnopka, L., Zdziarska, B., Pluta, A., Dmoszynska, A., Maj, S., Giebel, S., Zawilska, Z., Kbmarnicki, M. and Kloczko, I. (2001) "An original, multicenter randomized phase III trial comparing 2-CdA combined with cytarabine and daunorubicin (DAC-7) with standared cytarabine and daunorubicin (DA-7) for remission induction therapy in newly diagnosed, adult acute myeloid leukemia", Blood 98, 592a, (Abstract No 2481).
  • Konwalinka, G., Helson, C., Braverman, S., Petzer, G., Bilgeri, R. and Zihan, U. (1992) "Growth inhibitory properties of 2-chlorodeoxyadenosine (2-CdA). Growth inhibitory system tumors", In: Abraham, N.G., Konwalinka, G. and Marks, P., eds, Molecular Biology of Hematopoiesis (Intercept Ltd, Hanover, MA), pp. 603-613.
  • Zinzani, PL., Buzzi, M., Farabegoli, P., Martinelli, G., Tosi, P., Zuffa, E., Visani, G., Testoni, N., Salvucci, M., Bendandi, M., Zaccari, A. and Tura, S. (1994) "Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells", Haematologica 79, 127-131.
  • Marks, R.S., Letendre, L., Reid, J.M., Bagniewski, PG. and Ames, M.M. (1994) "A phase I and pharmacologie study of chlorodeoxyadenosine in patients with chronic myelomonocytic or chronic granulocytic leukemias", Proceedings of the American Society of Clinical Oncology 13, 155, (Abstract 415).
  • Dann, E.J., Anastasi, J. and Larson, A. (1998) "High dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase", Journal of Clinical Oncology 16, 1498-1504.
  • Martinelli, G., Testoni, N., Zuffa, E., Visani, G., Zinzani, P.L., Zaccaria, A., Farabegoli, P., Arginati, M., Amabile, M. and Tura, S. (1996) "FLANG (Fludarabine + cytosine arabinoside+ novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+ chronic myelogenous leukaemia", Leukemia and Lymphoma 22, 173-176.
  • Tedeschi, A., Montillo, M., Ferrara, P., Nosari, A., MeIe, G., Copia, C., Leoni, P. and Morra, E. (2000) 'Treatment of chronic myleoid leukemia in the blastic phase with fludarabine, cytosine arabionoside and G-CSF (FLAG)", European Journal of Haematology 64, 182-187.
  • Sacchi, S., Kantarjian, H.M., O'Brien, S., Cortes, I., Rios, M.B., Giles, F.I., Beran, M., Koller, C.A., Keating, M.J. and Talpaz, M. (1999) "Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of die results of first salvage therapy with three different treatment approaches for 162 patients", Cancer 86, 2632-2641.
  • Druker, B.J., Talpaz, M., Resta, DJ., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., OhnoJones, S. and Sawyers, CL. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myleoid leukemia", New England of Journal of Medicine 344, 1031-1037.
  • Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W.N., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russel, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Contre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gretwohl, A., Mandelli, P., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. and Druker, B.J. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myleoid blast crisis: results of a phase II study", Blood 99, 3530-3539.
  • Korycka, A. and Robak, T. (2002) "The comparison of influence of STI 571 used alone or in combination with 2-chlorodeoxyadenosine or fludarabine on the normal and chronic myelogenous leukemia progenitor cells in vitro", Hematology, Journal 3(Suppl. 1), 292, (Abstract 985).
  • Robak, T. and Korycka, A. (1995) "The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon-á (IFN-a) or interferon-? (IFN-?) on granulocyte macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in in vitro cultures", Leukemia and Lymphoma 21, 161-168.
  • Visani, G., Lemoli, R.M., Tosi, P., Martinelli, G., Testoni, N., Ricci, P., Piccaluga, PP., Pastano, R., Leopardi, G., Dizdari, A., Motta, M.R., Rizzi, S. and Tura, S. (1999) "Fludarabine containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients", British Journal of Haematology 105, 775-779.
  • Visani, G., Lemoli, R.M., Isidori, A., Piccaluga, P.P., Martinelli, G., Malagola, M., Gugliotta, L., Bonini, A., Bonifazi, F., Motta, M.R., Rizzi, S., Castellani, S. and Tura, S. (2001) "Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients", Bone Marrow Transplantation 27, 829-835.
  • Byrne, J.L., Dasgupta, E., Pallis, M., Turzanski, J., Forman, K., Mitchell, D., Haynes, A.P. and Russel, N.H. (1999) "Early allogenic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG", Leukemia 13,786-791.
  • Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, I., Mehra, R., Clastion, D., Andersson, B., Beran, M, Przepiorka, D., Koller, I.C., Kbmblau, S., Korbling, M., Rearing, M., Kantarjian, H. and Champlin, R. (1997) "Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy", Blood 89, 4531-4536.
  • Khouri, I.F., Rearing, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. and Champlin, R. (1998) 'Transplant-like: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies", Journal of Clinical Oncology 16, 2817-2824.
  • Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y, Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Sannel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. and Or, R. (1998) "Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases", Blood 91, 756-763.
  • Giralt, S., Thall, P., Khouri, S., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Bruton, J., Cohen, A., Davis, M., Andersson, B.S., Anderlini, P., Gayewski, J., Kornblau, S., Andreef, M., Przepiorka, D., Ueno, N.T., Mildrem, J. and Champlin, R. (2001) "Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hématologie malignancies undergoing allogenic progenitor cell transplantation", Blood 97, 631-637.
  • Saito, T., Kanda, Y., Kami, M., Kato, K., Shoji, N., Kanai, S., Ohnishi, T., Kawano, Y., Nakai, K., Ogasawara, T., Matsubara, H., Makimoto, A., Tanosaki, R., Tobinai, K., Wakasugi, M., Takane, Y. and Mineishi, S. (2002) "Therapeutic potential of a reducedintensity preparative regimen for allogenic transplantation with cladribine, busulfan and antithymocyte globulin against advanced/ refractory acute leukemia/lymphoma", Clinical Cancer Research 8, 1014-1020.
  • Michallet, M., Bilger, K., Garban, E, Altai, M., Huyn, A., Biaise, D., Milpied, N., Moreau, P., Bordigoni, P., Kuentz, M., Sadoun, A., Cahn, J.Y., Socie, G., Thomas, X., Arnand, P., Raus, N., Lheritier, V, Pigneux, A. and Boiron, J.M. (2001) "Allogenic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome", Journal of Clinical Oncology 19, 3340-3349.
  • Bornhauser, M., Thiede, C., Schuler, U., Platzbecker, U., FreibergRichter, J., Helwig, A., Plettig, R., Rollig, C., Neumann, R., Kroschinsky, F., Neubauer, A. and Ehninger, G. (2000) "Dose reduced conditioning for allogenic blood stem cell transplantation: durable engraftment without antithymocyte globulin", Bone Marrow Transplantation 26, 119-125.
  • Kroger, N., Schetelig, I., Zabelina, T., Kruger, W., Rengens, H., Starte, N., Schrum, J., Kabisch, H., Siegert, W. and Zander, A.R. (2001) "A fludarabine-based dose-reduced conditioning regimen followed by allogenic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome", Bone Marrow Transplantation 28, 643-647.
  • Schlenk, R.F., Hartmann, F., Hensel, M., lung, W., Weber-Nordt, R., Gabler, A., Haas, R., Ho, A.D., Tromper, L. and Dohner, H. (2002) "Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCTE) followed by allogenic unselected peripheral blood stem cell transplantation in elderly patients with leukemia", Leukemia 16, 581-586.
  • Wasch, R., Reisser, I., Hahn, J., Bertz, H., Engelhardt, M., Kunzmann, R., Veelken, H., Holler, E. and Finke, J. (2002) "Rapid achievement of complete chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogenic transplantation", Bone Marrow Transplantation 26, 245-250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.